Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Galt Pharmaceuticals LLC
WARNING LETTER
•Galt Pharmaceuticals LLC•September 13, 2019

Galt Pharmaceuticals LLC – FDA Warning Letter, Sep 13, 2019

Record Details

The FDA's Office of Prescription Drug Promotion (OPDP) issued a Warning Letter to Galt Pharmaceuticals, LLC (Galt) regarding a professional email (GLT-DOR-016) for DORAL (quazepam) tablets. The email was found to contain false or misleading claims about Doral's risks and efficacy, thereby misbranding the drug and making its distribution violative under the Federal Food, Drug and Cosmetic Act (FD&C Act).

Key violations include: 1. **False or Misleading Risk Presentation:** The email omitted crucial warnings and precautions, such as benzodiazepine withdrawal syndrome, detailed CNS-depressant effects, severe anaphylactic/anaphylactoid reactions, abnormal thinking/behavior changes, and worsening of depression. It also misleadingly minimized abuse and dependence risks by suggesting Doral has a lower abuse potential than other prescription and OTC products, despite being a C-IV controlled substance. 2. **False or Misleading Claims about Efficacy:** The email falsely claimed Doral is the "only marketed medication for Insomnia that helps with all three important components of sleep," when other medications exist. 3. **Omission of Material Facts:** The email omitted information from the Indications and Usage section of the PI, specifically that prolonged administration is generally not necessary or recommended, and that insomnia may be a symptom of other disorders requiring specific treatment.

These violations are particularly concerning due to Doral being a controlled substance with a Boxed Warning

Company
Galt Pharmaceuticals LLC
Inspection date
September 13, 2019
Product type
Drugs
Office
Office of Prescription Drug Promotion
Person
  • Andrew S.T. Haffer
View Company Profile

ID · 75a8d0ef-a8bb-4842-8ee1-d2605677a6f5

Violation Codes5
21 U.S.C. 331(a)21 U.S.C. 352(a)21 U.S.C. 352(n)21 U.S.C. 321(n)21 CFR 202.1(e)(5)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Galt Pharmaceuticals LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.